TEVOGEN BIO HOLDINGS I

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

22 May 2025 10:21:42 By Nasdaq GlobeNewswire

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

12 May 2025 05:00:00 By Nasdaq GlobeNewswire

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

02 May 2025 12:45:14 By Nasdaq GlobeNewswire

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

30 Apr 2025 12:49:52 By Nasdaq GlobeNewswire

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

29 Apr 2025 10:48:02 By Nasdaq GlobeNewswire

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

29 Apr 2025 05:00:01 By Nasdaq GlobeNewswire

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

28 Apr 2025 13:36:57 By Nasdaq GlobeNewswire

Tevogen Bio Announces 2025 Annual Meeting

25 Apr 2025 11:33:05 By Nasdaq GlobeNewswire

Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility

17 Apr 2025 11:54:18 By Nasdaq GlobeNewswire

Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

15 Apr 2025 11:03:00 By Nasdaq GlobeNewswire

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

14 Apr 2025 10:53:50 By Nasdaq GlobeNewswire

Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States

09 Apr 2025 11:45:39 By Nasdaq GlobeNewswire

Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs

08 Apr 2025 14:53:05 By Nasdaq GlobeNewswire

Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission

07 Apr 2025 12:58:27 By Nasdaq GlobeNewswire

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

26 Mar 2025 12:12:23 By Nasdaq GlobeNewswire

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

25 Mar 2025 10:11:06 By Nasdaq GlobeNewswire

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

10 Mar 2025 09:40:32 By Nasdaq GlobeNewswire

Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel

07 Mar 2025 13:09:46 By Nasdaq GlobeNewswire

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

03 Mar 2025 09:52:45 By Nasdaq GlobeNewswire

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

28 Feb 2025 10:17:46 By Nasdaq GlobeNewswire